Seaweed compound shows promise for prostate relief

The 90-day study, conducted by the Australian biotechnology firm Marinova and published in Research and Reports in Urology, tracked 88 men aged 45 to 80. Participants who received the daily fucoidan supplement reported a nine-fold improvement in voiding symptoms—such as weak stream and straining—and a two-fold increase in storage symptom management, including reduced frequency and urgency. Lead researcher Dr. Barbara Wimmer noted that the compound remained safe throughout the duration of the trial, offering a rare clinically validated natural alternative for a condition that affects up to 90% of men in their 80s.

Researchers utilized the International Prostate Symptom Score to quantify these outcomes. Beyond the physiological changes, participants recorded a marked increase in overall quality of life. Following these results, Marinova intends to pursue the commercialization of its fucoidan compounds to address the widespread prevalence of the condition, marking a shift toward integrating marine-based bioactives into standard urological care.